Anti-IFN-α therapy and other new drugs (including peptidylarginine deiminase inhibitor 4, N-acetylcysteine and DNase I) can target NETs and have potential in the therapy of autoimmune diseases (183). The gene discussed is IFNA1; the disease is autoimmune disease.